About this trial
This study aims to evaluate the efficacy and safety of combining papaverine with oxytocin for labor induction compared to oxytocin alone
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women with a singleton pregnancy Over the age of 18 Term (between 37-42 weeks of gestation) A medical decision for labor induction using oxytocin. Cephalic presentation Viable fetus nulliparity
Disqualifiers
parity >1
Twin pregnancy Women with a previous cesarean section Severe fetal anomalies Women with psychiatric disorders, including depression and schizophrenia. Contraindication to vaginal delivery Women unable to sign the consent form Women known to have SVT (supraventricular tachycardia). Women with a heart rate over 100 or arrhythmia Known sensitivity to any component of the drug Liver disease
Trial design
Parallel
Treatments tested in this trial
Papaverine
Drugpapaverine a smooth muscle relaxant
normal saline
Drugnormal saline 0.9% 100 cc
Treatment groups
Trial outcomes
Primary outcomes
time to active delivery
time from labor induction till dilatation of 6 cm
Secondary outcomes
vaginal deliveries in 24 hours
rate of vaginal deliveries in 24 hours
total length of labor
time for induction to delivery
cesarean delivery rate
rate of emergent cesarean delivery during labor
length of second stage of labor
second stage of labor in hours
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: